[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568448":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with high-risk AML, ALL or MDS",null,"Patients with high-risk AML, ALL or MDS treated in the hematology department of Nantes University Hospital.\n\nAccording to the needs of ongoing biological studies, additional volumes may be collected during blood and bone marrow sampling for diagnosis or relapse at inclusion , with up to one additional sample each month for three months following inclusion",[13],{"name":14,"affiliation":5,"role":15},"Pierre Peterlin","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Pierre Perterlin","CONTACT","+33 2 40 08 32 71","Pierre.PETERLIN@chu-nantes.fr",[23],{"facility":5,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Nantes","France","FR",{"type":29,"coordinates":30},"Point",[31,32],-1.55336,47.21725,{"lat":32,"lon":31},[35],{"name":36,"role":19,"phone":37,"phoneExt":10,"email":38},"Nicoletta Libera LILLI","+33 2 76 64 37 83","nicolettalibera.lilli@chu-nantes.fr",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568448","creation-of-a-biocollection-of-patients-with-acute-myeloid-leukemia-aml-or-lymphoid-leukemia-all-or-high-risk-myelodysplastic-syndrome-mds-monitored-at-the-nantes-university-hospital-100568448",false,"NCT06681363","Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","LANA","Inclusion Criteria:\n\n* Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment\n* Patient who has signed the consent form.\n* Patient affiliated with a social security system.\n\nExclusion Criteria:\n\n* Minor patients.\n* Adults under guardianship.\n* Protected persons","ALL","18 Years",{"count":51,"type":52},1000,"ESTIMATED","OBSERVATIONAL","The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or myelodysplastic cells for the research teams of the National Institute of Health and Medical Research (INSERM). To do this, an additional blood or bone marrow sample to those planned in the context of patient care will be collected after signing consent. These samples will then be sent directly to the INSERM teams for immediate analysis with the aim to conduct research aimed at a better understanding of AML, ALL or MDS and improving treatments",[56,57,58],"Acute Myeloid Leucemia","High-risk Myelodysplastic Syndrome (MDS)","Acute Lymphoid Leukemia",[60,61],"high-risk myelodysplactic syndrome","Acute leukemia","2026-05-26",{"date":64,"type":65},"2026-05-29","ACTUAL",{"date":67,"type":65},"2026-05-21",{"date":69,"type":52},"2036-05-21",{"name":5,"class":6},1]